

Boe Sandahl Sorensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6928033/publications.pdf>

Version: 2024-02-01

91
papers

2,995
citations

218381

26
h-index

189595

50
g-index

92
all docs

92
docs citations

92
times ranked

5250
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 43-50.	1.2	7
2	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. <i>Case Reports in Oncology</i> , 2022, 14, 1323-1327.	0.3	4
3	The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. <i>Cells</i> , 2022, 11, 2170.	1.8	10
4	Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma. <i>Cancers</i> , 2022, 14, 3342.	1.7	9
5	Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 376.	1.1	7
6	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. <i>Clinical Lung Cancer</i> , 2021, 22, e870-e877.	1.1	6
7	STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	2.0	7
8	<i>EGFR</i> transcription in nonâ€smallâ€cell lung cancer tumours can be revealed in ctDNA by cellâ€free chromatin immunoprecipitation (cfChIP). <i>Molecular Oncology</i> , 2021, 15, 2868-2876.	2.1	7
9	cGAS-STING pathway expression as a prognostic tool in NSCLC. <i>Translational Lung Cancer Research</i> , 2021, 10, 340-354.	1.3	18
10	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 37-43.	0.9	24
11	Neurofilament Light Chain as A Biomarker for Brain Metastases. <i>Cancers</i> , 2020, 12, 2852.	1.7	20
12	Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells. <i>Translational Lung Cancer Research</i> , 2020, 9, 1904-1914.	1.3	13
13	Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2020, 147, 244-251.	0.9	12
14	TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1433-1440.	0.6	28
15	Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 1414.	1.7	15
16	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. <i>Lung Cancer</i> , 2020, 143, 67-72.	0.9	17
17	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 947.	1.7	20
18	Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 11542.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 135, 92-96.	0.9	22
20	Intra-individual variation of circulating tumour DNA in lung cancer patients. <i>Molecular Oncology</i> , 2019, 13, 2098-2106.	2.1	14
21	Day-to-day and within-day biological variation of cell-free DNA. <i>EBioMedicine</i> , 2019, 49, 284-290.	2.7	49
22	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Non-small cell Lung Cancer Treated With Erlotinib. <i>Clinical Lung Cancer</i> , 2019, 20, 161-166.e1.	1.1	13
23	Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC. <i>Translational Oncology</i> , 2019, 12, 432-440.	1.7	20
24	The prognostic role of inflammation-scores on overall survival in lung cancer patients. <i>Acta Oncologica</i> , 2019, 58, 371-376.	0.8	15
25	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. <i>BMC Cancer</i> , 2018, 18, 191.	1.1	14
26	Detection of EGFR Variants in Plasma. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 483-494.	1.2	37
27	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. <i>Oncotarget</i> , 2018, 9, 31066-31076.	0.8	18
28	Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer. <i>Tumor Biology</i> , 2018, 40, 101042831881120.	0.8	10
29	Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing. <i>Translational Oncology</i> , 2018, 11, 1220-1224.	1.7	63
30	Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer. <i>Tumor Biology</i> , 2017, 39, 101042831773097.	0.8	18
31	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2017, 117, 704-709.	2.9	45
32	Soluble HER3 predicts survival in bladder cancer patients. <i>Oncology Letters</i> , 2017, 15, 1783-1788.	0.8	5
33	Increased PD-L1 expression in erlotinib-resistant NSCLC cells with <i>MET</i> gene amplification is reversed upon MET-TKI treatment. <i>Oncotarget</i> , 2017, 8, 68221-68229.	0.8	31
34	IGF1R depletion facilitates <i>MET</i> -amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells. <i>Oncotarget</i> , 2017, 8, 33300-33315.	0.8	23
35	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 172-182.	1.3	80
36	Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. <i>Stem Cells International</i> , 2016, 2016, 1-8.	1.2	12

#	ARTICLE	IF	CITATIONS
37	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. <i>Translational Oncology</i> , 2016, 9, 505-511.	1.7	13
38	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 243-248.	0.6	2
39	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , 2016, 94, 81-87.	0.9	34
40	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib. <i>Lung Cancer</i> , 2016, 100, 77-84.	0.9	97
41	Exosomal Proteins as Diagnostic Biomarkers in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1701-1710.	0.5	213
42	Gene Expression of the EGF System as a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations. <i>Translational Oncology</i> , 2016, 9, 306-312.	1.7	7
43	Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1 β down-regulation in metastatic cells. <i>BMC Cancer</i> , 2016, 16, 32.	1.1	13
44	Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 26659.	5.5	242
45	Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer. <i>BJU International</i> , 2015, 115, 163-165.	1.3	14
46	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. <i>Lung Cancer</i> , 2015, 90, 314-320.	0.9	13
47	Abstract 5064: EGFR and HER3 are important in the interaction between lung cancer cells and fibroblasts. , 2015, , .		0
48	Expression of the EGF Family in Gastric Cancer: Downregulation of HER4 and Its Activating Ligand NRG4. <i>PLoS ONE</i> , 2014, 9, e94606.	1.1	39
49	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. <i>Cancer</i> , 2014, 120, 3896-3901.	2.0	180
50	Expression of the epidermal growth factor system in human middle ear cholesteatoma. <i>Acta Oto-Laryngologica</i> , 2014, 134, 124-134.	0.3	6
51	HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma. <i>Melanoma Research</i> , 2014, 24, 88-91.	0.6	15
52	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 224-230.	0.9	41
53	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. <i>Lung Cancer</i> , 2014, 85, 435-441.	0.9	11
54	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. <i>BMC Cancer</i> , 2014, 14, 294.	1.1	135

#	ARTICLE	IF	CITATIONS
55	The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor $\hat{\pm}$ is not expressed. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2013, 73, 503-513.	0.6	5
56	Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases. <i>SpringerPlus</i> , 2013, 2, 464.	1.2	12
57	Estrogen receptor $\hat{\pm}$ is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 71-80.	1.1	59
58	A Single Rainbow Trout Cobalamin-binding Protein Stands in for Three Human Binders. <i>Journal of Biological Chemistry</i> , 2012, 287, 33917-33925.	1.6	12
59	Hypoxia Changes the Expression of the Epidermal Growth Factor (EGF) System in Human Hearts and Cultured Cardiomyocytes. <i>PLoS ONE</i> , 2012, 7, e40243.	1.1	28
60	Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1287-1289.	0.5	124
61	Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1946-1949.	0.5	12
62	Calcium-induced apoptosis is delayed by HER1 receptor signalling through the Akt and PLC $\hat{\beta}$ 3 pathways in bladder cancer cells. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 45-51.	0.6	2
63	Identifying responders to trastuzumab therapy in breast cancer. <i>Future Oncology</i> , 2011, 7, 767-773.	1.1	5
64	Mouse Transcobalamin Has Features Resembling both Human Transcobalamin and Haptocorrin. <i>PLoS ONE</i> , 2011, 6, e20638.	1.1	34
65	Transcobalamin deficiency caused by compound heterozygosity for two novel mutations in the <i>TCN2</i> gene: a study of two affected siblings, their brother, and their parents. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 269-274.	1.7	11
66	Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. <i>Anticancer Research</i> , 2010, 30, 2463-8.	0.5	16
67	Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts. <i>Cancer Research</i> , 2009, 69, 873-878.	0.4	164
68	Expression of the Epidermal Growth Factor System in Eutopic Endometrium from Women with Endometriosis Differs from That in Endometrium from Healthy Women. <i>Gynecologic and Obstetric Investigation</i> , 2009, 67, 118-126.	0.7	16
69	Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 263-75.	1.1	129
70	Quantitative real-time RT-PCR in sentinel lymph nodes from melanoma patients.. <i>Apmis</i> , 2008, 116, 199-205.	0.9	7
71	A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. <i>Acta Oncologica</i> , 2008, 47, 618-632.	0.8	24
72	Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: Identification of a specific insulin-responsive promoter element. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 885-891.	1.0	17

#	ARTICLE	IF	CITATIONS
73	Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. <i>BJU International</i> , 2007, 99, 196-201.	1.3	5
74	Expression of the epidermal growth factor system in endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2007, 104, 158-167.	0.6	49
75	Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 798-804.	0.8	71
76	Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system. <i>FEBS Journal</i> , 2006, 273, 5479-5489.	2.2	16
77	Circulating Tyrosinase and MART-1 mRNA does not Independently Predict Relapse or Survival in Patients with AJCC Stage II Melanoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 849-854.	0.3	8
78	The chemotherapeutic agent VP16 increases the stability of HB-EGF mRNA by a mechanism involving the 3' UTR. <i>Experimental Cell Research</i> , 2006, 312, 3651-3658.	1.2	8
79	Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. <i>Melanoma Research</i> , 2005, 15, 409-416.	0.6	30
80	Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation: impact of specific HER1 inhibition. <i>Prostate</i> , 2005, 64, 1-8.	1.2	20
81	Pathologic Assessment of Melanoma Sentinel Nodes: A Role for Molecular Analysis Using Quantitative Real-Time Reverse Transcription-PCR for MART-1 and Tyrosinase Messenger RNA. <i>Clinical Cancer Research</i> , 2005, 11, 1425-1433.	3.2	23
82	The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. <i>Molecular and Cellular Biochemistry</i> , 2004, 260, 129-135.	1.4	11
83	S100 β protein in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2004, 14, 211-215.	0.6	8
84	The Influence of Immunohistochemistry on mRNA Recovery from Microdissected Frozen and Formalin-Fixed, Paraffin-Embedded Sections. <i>Diagnostic Molecular Pathology</i> , 2004, 13, 224-233.	2.1	27
85	ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. <i>Prostate</i> , 2003, 56, 142-149.	1.2	39
86	Transcellular Transport of Vitamin B12 in LLC-PK1 Renal Proximal Tubule Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1099-1106.	3.0	23
87	Simultaneous Quantitation of Several mRNA Species by Calibrated Reverse Transcription Polymerase Chain Reaction and Capillary Electrophoresis: Analysis of the Epidermal Growth Factor Receptor and its Activating Ligands EGF, TGF α , and HB-EGF in Rat Liver. <i>Laboratory Investigation</i> , 2000, 80, 983-986.	1.7	6
88	Quantitation of the mRNA expression of the epidermal growth factor system: Selective induction of heparin-binding epidermal growth factor-like growth factor and amphiregulin expression by growth factor stimulation of prostate stromal cells. <i>Translational Research</i> , 2000, 136, 209-217.	2.4	13
89	Epidermal growth factor and insulin-like growth factor I upregulate the expression of the epidermal growth factor system in rat liver. <i>Journal of Hepatology</i> , 2000, 32, 645-654.	1.8	8
90	Different modes of anthracycline interaction with topoisomerase II. <i>Biochemical Pharmacology</i> , 1993, 45, 2025-2035.	2.0	60

#	ARTICLE	IF	CITATIONS
91	Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-yl)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16). <i>Biochemical Pharmacology</i> , 1993, 46, 389-393.	2.0	80